EOLS Evolus, Inc.

NEUTRAL Impact: 3/10 S-3
Horizon months Filed Jun 5, 2026 Processed 7d 18h ago SEC 0001570562-26-000071
Shelf registration — potential dilution

Price Chart

Loading chart...

Executive Summary

Evolus filed a new universal shelf registration statement (S-3) replacing its expiring 2023 shelf, registering up to $250M in securities (common, preferred, debt, warrants, units, rights). The filing includes $195.5M of unsold securities carried forward from the prior shelf. This is a routine shelf replacement — no immediate offering is announced, but it provides the company with flexible capital-raising capacity for the next three years.

Key Financial Metrics

Offering Size
$250.0M

Actionable Insight

Routine shelf replacement with no immediate offering — monitor for future prospectus supplements that would signal actual capital raise. The $195.5M carry-forward from the prior shelf suggests the company has had ample shelf capacity unused. Given the company's $435M market cap, a full $250M draw would represent ~57% dilution, but the filing itself is not an offering event.

Key Facts

  • New S-3 shelf registration filed June 5, 2026, replacing expiring 2023 shelf (File No. 333-270370)
  • Maximum aggregate offering price: $250,000,000
  • Includes $195,519,553 of unsold securities carried forward from prior shelf per Rule 415(a)(6)
  • Securities registered: common stock, preferred stock, debt securities, warrants, units, rights
  • Registration fee paid: $7,523.75
  • Common stock listed on Nasdaq under EOLS; last sale price $6.60 on June 4, 2026
  • Company had $435M market cap at filing time
  • Prior shelf was set to expire June 7, 2026

Financial Impact

Up to $250M in potential future capital raises; no immediate dilution

dilutiondebt capacity

Risk Factors

  • Future offerings under this shelf could cause dilution to existing shareholders
  • Debt securities issuance could increase leverage
  • No specific use of proceeds disclosed — general corporate purposes expected

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001570562-26-000071
Exhibit: exfilingfees.htm0001570562-26-000071
Exhibit: exhibit51-sx32026.htm0001570562-26-000071
Exhibit: exhibit231-sx32026.htm0001570562-26-000071
Document: evoluss-32026.htm0001570562-26-000071
Document: 0001570562-26-000071-index-headers.html0001570562-26-000071
Document: 0001570562-26-000071-index.html0001570562-26-000071
Document: 0001570562-26-000071.txt0001570562-26-000071
4 reports for EOLS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for EOLS — sortable, filterable
Type Now
Jun 5, 2026
7d ago
S-3
NEUTRAL ★ 3/10
$6.82 awaiting T+20awaiting T+20$6.73 (−1.32%)
Apr 29, 2026
6w ago
DEFA14A
NEUTRAL ★ 3/10
$5.18 $6.18▲ +19.30%▲ +13.85%$6.73 (+29.92%)
Mar 17, 2026
12w ago
Insider Cluster
BEARISH ★ 6/10
$4.91 $4.63▲ +5.70%▲ +10.00%$6.73 (−37.07%)
Mar 17, 2026
12w ago
Insider Cluster
BEARISH ★ 7/10
$4.91 $4.63▲ +5.70%▲ +10.00%$6.73 (−37.07%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (46h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access